China has approved four major domestic PD-1 inhibitors with strong clinical evidence in multiple tumour types. The cost gap with Keytruda is enormous — but so are the indication differences. Here is the careful comparison.
China's domestic PD-1 inhibitor pipeline has produced four molecules with broad NMPA approval and substantial clinical evidence:
The Drugs and Their Approvals
China's domestic PD-1 inhibitor pipeline has produced four molecules with broad NMPA approval and substantial clinical evidence:
- Tislelizumab (BeiGene, Tevimbra): approved internationally including FDA, EMA — broadest global footprint
- Sintilimab (Innovent, Tyvyt): NSCLC, classical Hodgkin lymphoma, hepatocellular carcinoma, and several other indications
- Camrelizumab (Jiangsu Hengrui): hepatocellular carcinoma (with rivoceranib), NSCLC, oesophageal carcinoma, classical Hodgkin lymphoma
- Toripalimab (Junshi, Loqtorzi): nasopharyngeal carcinoma — first FDA-approved domestic Chinese PD-1
All are approved through robust Phase III trials, many head-to-head against pembrolizumab (Keytruda) or with active comparators.
The Cost Gap
Pembrolizumab (Keytruda) lists at approximately USD 11,000 per dose in the US. Domestic Chinese PD-1 inhibitors typically dose at USD 1,200–2,200 per dose for international patients at Class A centres — and substantially less under Chinese national reimbursement programs for citizens.
For a patient on a 2-year treatment course (every 3 weeks), that's a savings of USD 250,000–350,000.
The Clinical Equivalence Question
Are these drugs equivalent? For most established indications, head-to-head and meta-analytic data show no clinically meaningful difference between approved domestic Chinese PD-1 inhibitors and pembrolizumab/nivolumab. Tislelizumab in particular has the broadest international evidence base, with FDA approval for oesophageal squamous cell carcinoma, NSCLC, and hepatocellular carcinoma based on Phase III trials enrolling in multiple countries.
Differences exist in specific indications. Pembrolizumab has approvals in some tumour types (e.g. specific MSI-H/dMMR contexts) where Chinese alternatives have less data. Oncologists at Class A cancer centres present these distinctions clearly when relevant.
The Workup and Companion Diagnostics
PD-1 inhibitor selection depends on:
- Tumour type and stage
- PD-L1 expression (TPS or CPS depending on context)
- MSI status, tumour mutation burden in selected contexts
- Specific NMPA-approved indications for each molecule
Class A oncology centres run the full companion diagnostic workup — typically USD 300–500 for the molecular profile.
What's Different from 2-3 Years Ago?
Two updates: (1) tislelizumab and toripalimab now have FDA approvals, validating their evidence base internationally; (2) several second-generation Chinese PD-1 / PD-L1 / bispecific antibodies are progressing through trials, with international filings expected.
How to Decide
If you're considering immune checkpoint therapy and the cost differential is meaningful for you, request a written second opinion from a Class A oncology centre. The opinion will assess your specific tumour profile, recommended regimen, and most appropriate molecule. See our remote second opinion page for the workflow.
Sources: FDA approval documents for tislelizumab and toripalimab; NMPA approval registry; published Phase III trial data; partner-hospital oncology pricing 2026.